NEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN) on behalf of Regeneron stockholders. Our investigation concerns whether Regeneron has violated the federal securities laws and/or engaged in other unlawful business practices.
Click here to participate in the action.
Regeneron is the subject of a DOJ lawsuit filed on April 10, 2024. The lawsuit accuses Regeneron of failing to report millions of dollars in discounts given to drug distributors. These discounts were provided as reimbursements for credit card processing fees. As a result, the DOJ alleges that the average selling price of Regeneron's Eylea drug was inflated above the amount allowed by Medicare.
If you purchased or otherwise acquired Regeneron shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com
